Research To Practice | Oncology Videos

Latest Episodes:

Endometrial Cancer | The Implications of New Research Findings for the Management of Endometrial Cancer Jul 14, 2023

Show notes

Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell, including the following topics:

Introduction (0:00)
First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Powell (7:32)
Current Options for Relapsed EC; Promising Investigational Agents and Strategies — Dr Monk (32:39)
Clinical Investigator Survey (43:41)

CME information and select publications

Gastroesophageal Cancers | Lunch with the Investigators: Gastroesophageal Cancers Jul 13, 2023

Show notes

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Dr Harry H Yoon, including the following topics:

Integration of Immune Checkpoint Inhibitors into the Management of HER2-Negative Gastroesophageal (GE) Cancers
- Introduction (0:00)
- Adjuvant immunotherapy for GE cancers (1:54)
- First-line anti-PD-1/PD-L1 antibody-based regimens for metastatic HER2-negative GE cancer (13:11)
- Future role of novel immunotherapies/checkpoint inhibitors (20:57)
Optimal Management of HER2-Positive GE Cancers
- Selection of first-line therapy for metastatic HER2-positive GE cancer (28:37)
- Selection of second-line therapy for metastatic HER2-positive GE cancer (36:56)
Therapeutic Options for Relapsed/Refractory GE Cancers; Novel Investigational Approaches
- Selection of second-line therapy for metastatic HER2-negative GE cancer (42:11)
- Zolbetuximab/chemotherapy as first-line therapy for claudin 18.2-positive metastatic GE cancer (43:09)
- Use of circulating tumor DNA assays for patients with GE cancers (53:37)

CME information and select publications

Prostate Cancer | Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer Jul 12, 2023

Show notes

Featuring perspectives from Dr Emmanuel S Antonarakis, Prof Karim Fizazi, Dr Rana R McKay, Dr Alicia K Morgans and Dr A Oliver Sartor, including the following topics:

Current Management of Nonmetastatic Prostate Cancer
- Introduction (0:00)
- Case: A man in his early 70s diagnosed with localized prostate cancer who underwent a radical prostatectomy in 2010 experiences rising prostate-specific antigen (PSA) from 0.18 to 0.4; PSA doubling time 7 months; PSMA PET-negative for other sites of disease — David S Morris, MD (1:26)
- Case: A man in his early 70s with M0 hormone-sensitive prostate cancer (HSPC) with PSA persistence after radical prostatectomy received androgen deprivation therapy (ADT) intensification with abiraterone/prednisone and went to the ER with hypertension, palpitations, headache and abnormal liver function tests — Sandy Srinivas, MD (15:58)
- Faculty presentation: Dr Morgans (19:29)
New Considerations in Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Case: A man in his mid 60s with localized prostate cancer and biochemical recurrence 5 years after neoadjuvant and adjuvant leuprolide and intensity-modulated radiotherapy to the whole pelvis — Neeraj Agarwal, MD, FASCO (28:59)
- Case: A man in his early 80s who underwent radical prostatectomy 15 years ago and received radiotherapy and ADT for biochemical recurrences is now diagnosed with M0 castration-resistant prostate cancer with quickly rising PSA levels — Dr Morris (33:02)
- Faculty presentation: Prof Fizazi (41:54)
Available and Emerging Strategies for Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Discussion (53:41)
- Case: A man in his mid 60s diagnosed with metastatic HSPC and PSMA positivity in the pubic ramus, bilateral external iliac nodes and lungs — Dr Srinivas (57:03)
- Faculty presentation: Dr McKay (1:03:01)
Identification and Management of mCRPC with a Homologous Recombination Repair (HRR) Gene Abnormality
- Case: A man in his early 50s with mCRPC after enzalutamide receives olaparib; somatic BRCA2 mutation; TP53 mutation on liquid biopsy — Dr Agarwal (1:18:21)
- Case: A man in his early 70s with high-grade localized prostate cancer treated with proton beam therapy and ADT for 2 years now has rising PSA and CT scan positive for retroperitoneal node; somatic BRCA2, TP53, FOXA1 and MEN1 mutations; microsatellite stable — Dr Morris (1:21:59)
- Faculty presentation: Dr Antonarakis (1:30:22)
Management of Progressive mCRPC
- Case: A man in his late 70s with multiregimen-refractory mCRPC and a gBRCA2 mutation receives olaparib with a sustained response for several years — Dr Srinivas (1:43:10)
- Faculty presentation: Dr Sartor (1:48:35)

CME information and select publications

Hodgkin and Non-Hodgkin Lymphoma | Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin Lymphoma Jul 10, 2023

Show notes

Featuring perspectives from Dr Ian W Flinn, including the following topics:

Hodgkin Lymphoma
- Introduction (0:00)
- Case: A man in his late 30s with well-controlled HIV and newly diagnosed Stage IV classic Hodgkin lymphoma receives brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD) — Neil Morganstein, MD (2:30)
- Case: A man in his early 60s with classic Hodgkin lymphoma with a left lower lung mass and extensive regional lymphadenopathy receives brentuximab vedotin with AVD on the Phase III SWOG-S1826 trial — Ranju Gupta, MD (6:45)
Mantle Cell Lymphoma (MCL)
- Case: A man in his late 50s with newly diagnosed MCL blastoid variant — Zanetta S Lamar, MD (16:27)
- Case: A man in his mid 50s with newly diagnosed Stage IV MCL — Shams Bufalino, MD (21:23)
Follicular Lymphoma
- Case: A man in his mid 60s with incidental diagnosis of Grade IIIA follicular lymphoma after admission to the hospital for a stroke — Bhavana (Tina) Bhatnagar, DO (36:28)
- Case: A woman in her late 30s with extensive lymphadenopathy is diagnosed with Grade I/II follicular lymphoma and receives bendamustine/rituximab — Dr Morganstein (39:04)
Diffuse Large B-Cell Lymphoma (DLBCL)
- Case: A physically independent man in his early 80s with DLBCL and multiple comorbidities, including cardiac issues and peripheral neuropathy, experiences disease progression after R-GCVP — Syed F Zafar MD (49:53)
- Case: A man in his mid 70s who presented with rapidly progressive proptosis of the left eye is diagnosed with DLBCL and receives R-CHOP and methotrexate CNS prophylaxis — Dr Lamar (55:21)

CME information and select publications

Colorectal and Gastroesophageal Cancers | What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Colorectal and Gastroesophageal Cancers Jul 07, 2023

Show notes

Featuring perspectives from Dr Kristen K Ciombor and Mrs Amanda K Wagner, including the following topics:

Introduction (0:00)
Colorectal Cancer (10:18)
Gastroesophageal Cancers (39:21)

NCPD information and select publications

Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma | Meet The Professors Live: Clinical Investigators Provide Perspectives on Actual Cases of Patients with Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma Jul 05, 2023

Show notes

Featuring perspectives from Dr John N Allan, Dr Shaji K Kumar, Dr Ann S LaCasce, Dr Sagar Lonial, Dr Loretta J Nastoupil and Dr Susan O'Brien, including the following topics:

Multiple Myeloma
- Introduction (0:00)
- Initial treatment of newly diagnosed multiple myeloma (MM) (1:51)
- Sequencing of therapies for relapsed/refractory MM (21:34)
Lymphoma
- Hodgkin lymphoma (52:12)
- Diffuse large B-cell lymphoma and follicular lymphoma (1:05:30)
- Mantle cell lymphoma (1:31:17)
Chronic Lymphocytic Leukemia
- First-line treatment of chronic lymphocytic leukemia (1:41:23)
- Relapsed/refractory disease (2:14:23)
- Richter's transformation (2:22:50)

CME information and select publications

Urothelial Bladder Cancer | Breakfast with the Investigators: Urothelial Bladder Cancer Jun 30, 2023

Show notes

Featuring perspectives from Dr Matthew D Galsky, Prof Andrea Necchi and Dr Scott T Tagawa, including the following topics:

Current and Future Management of Nonmetastatic Urothelial Bladder Cancer (UBC)
- Introduction (0:00)
- Management of non-muscle-invasive bladder cancer (5:30)
- Neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer (18:39)
- Management of nonmetastatic UBC in patients who are not candidates for cystectomy (27:55)
Recent Advances in the Treatment of Metastatic UBC (mUBC)
- Selection and sequencing of therapy for platinum-eligible patients with FGFR wild-type mUBC (31:03)
- Selection and sequencing of therapy for platinum-ineligible patients with FGFR wild-type mUBC (41:26)
- Selection and sequencing of therapy for patients with FGFR-altered mUBC (45:07)
- Novel agents and strategies under investigation in UBC (53:53)

CME information and select publications

Hepatobiliary Cancers | Breakfast with the Investigators: Hepatobiliary Cancers Jun 29, 2023

Show notes

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Robin K (Katie) Kelley and Prof Arndt Vogel, includingthe following topics:

Hepatocellular Carcinoma (HCC)
- Introduction (0:00)
- Adjuvant therapy for HCC (1:47)
- First-line systemic therapy for advanced/metastatic HCC (10:36)
- Management of HCC in the second-line setting and beyond (18:27)
Biliary Tract Cancers (BTCs)
- First-line systemic therapy for metastatic BTCs (26:41)
- Management of metastatic cholangiocarcinoma with FGFR fusions/rearrangements (35:16)
- Management of metastatic cholangiocarcinoma with IDH1 mutations (43:54)
- Management of metastatic HER2-positive BTC (48:47)

CME information and select publications

Ovarian Cancer | Breakfast with the Investigators: Ovarian Cancer Jun 27, 2023

Show notes

Featuring perspectives from Dr Philipp Harter, Dr David M O'Malley and Dr Shannon N Westin, including the following topics:

Up-Front Treatment for Advanced Ovarian Cancer (OC)
- Introduction (0:00)
- Front-line maintenance therapy for patients with advanced OC (3:11)
- Adverse events associated with PARP inhibitors and implications for therapeutic selection (14:17)
- Other considerations for patients with advanced ovarian cancer and germline BRCA mutations: Management of the breast, role of genetic counseling, et cetera (31:03)
The Evolving Management Paradigm for Relapsed/Refractory OC
- PARP inhibitors as later-line therapy for advanced OC (35:20)
- Use of mirvetuximab soravtansine in advanced OC (44:04)
Novel Agents and Strategies Under Investigation for Advanced OC
- Upifitamab rilsodotin in advanced OC (50:10)
- Tumor treating fields in advanced OC (56:03)

CME information and select publications

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Breast Cancer Jun 26, 2023

Show notes

Featuring perspectives from Dr Komal Jhaveri, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O'Shaughnessy, Dr Hope S Rugo and Prof Peter Schmid, including the following topics:

Long-Term Management of HER2-Positive Breast Cancer
- Introduction (0:00)
- Management of CNS-only disease progression in patients with HER2-positive metastatic breast cancer (2:27)
- Synergy between tucatinib and HER2-targeted antibody-drug conjugates (5:24)
- Management of trastuzumab deruxtecan–related adverse events (7:41)
- Patient selection for and practical implementation of postadjuvant neratinib (13:23)
- Faculty presentation: Dr Krop (16:26)
Optimizing the Management of ER-Positive Localized Breast Cancer
- Ovarian function suppression to preserve fertility and prevent premature ovarian insufficiency; interrupting adjuvant hormonal therapy to attempt pregnancy (24:56)
- Selection of patients for adjuvant tamoxifen monotherapy (29:05)
- Utility of genomic assays in the neoadjuvant setting; management of node-positive disease in postmenopausal patients with low-risk Recurrence Scores® (33:35)
- Selection between abemaciclib and ribociclib in the adjuvant setting (36:45)
- Potential utility of circulating tumor DNA assessment in breast cancer (41:58)
- Faculty presentation: Dr Kalinsky (46:36)
Considerations in the Care of Patients with ER-Positive Metastatic Breast Cancer
- Preference of CDK4/6 inhibitor in the metastatic setting (56:42)
- Sequencing of trastuzumab deruxtecan in ER-positive, HER2-low metastatic breast cancer (59:00)
- Faculty presentation: Dr Jhaveri (1:06:39)
Novel and Emerging Strategies for ER-Positive Metastatic Breast Cancer
- Selection of therapy for ER-positive metastatic breast cancer progressing on a CDK4/6 inhibitor; future role of capivasertib (1:19:31)
- Faculty presentation: Dr Rugo (1:30:39)
Evolving Clinical Decision-Making for Localized Triple-Negative Breast Cancer (TNBC)
- Management of localized TNBC; selection of patients for adjuvant Olaparib (1:46:10)
- PARP inhibitor tolerability (1:51:55)
- Faculty presentation: Dr O'Shaughnessy (1:55:31)
Recent Advances in the Treatment of Metastatic TNBC (mTNBC)
- Selection of therapy for triple-negative metastatic breast cancer; sequencing of trastuzumab deruxtecan in ER-negative, HER2-low disease (2:11:08)
- Faculty presentation: Prof Schmid (2:18:03)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected